Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease"

Inflamm Bowel Dis. 2019 Apr 11;25(5):e59. doi: 10.1093/ibd/izy273.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Inflammatory Bowel Diseases*

Substances

  • Antibodies, Monoclonal, Humanized
  • vedolizumab